Researchers have discovered a new survival strategy used by pancreatic cancer cells: sharing protein-making machinery through tiny cellular bridges called tunneling nanotubes (TNTs). Pancreatic ductal adenocarcinoma (PDAC) cells use these tubes to exchange messenger RNA, ribosomal components, and even fully assembled ribosomes, effectively supplying each other with the tools needed to make proteins and survive.
The study found that treatment with gemcitabine, a common chemotherapy drug, actually increases the formation of these nanotubes. Under stress from chemotherapy, cancer cells connect more, helping weaker cells by supplying functional ribosomes. Experiments showed that cells with impaired protein synthesis could regain their protein-making ability by receiving ribosomes from neighboring healthy cells.
This ribosome-sharing mechanism highlights a new way tumors resist treatment. By cooperating in this way, cancer cells protect vulnerable members of the population. Targeting TNTs could provide a new strategy to disrupt this support system and make chemotherapy more effective against pancreatic cancer.